Swiss Marine and Shipping Stock News

If you are wondering whether Sandoz Group is still attractively priced after its recent run, this article will help you size up what you are really paying for each Swiss franc of the business. The shares closed at CHF64.66, with a 7.0% return over the last month, a 13.0% return year to date, and a 71.1% return over the past year, although the last 7 days saw an 8.1% decline that may have changed how some investors view the risk and reward trade off. Recent news flow around Sandoz Group has...

Galderma Group (SWX:GALD) reports full year sales above $5b, marking a milestone for its dermatology focused portfolio. The company highlights new product launches it describes as having blockbuster potential across its prescription and aesthetics segments. Fresh clinical data show Nemluvio delivering long term efficacy and safety in prurigo nodularis, an area of high unmet medical need. Regulatory approval of new device technology supports further expansion of Galderma's aesthetics...

Adecco Group (SWX:ADEN) shares are in focus after the company reported fourth quarter and full year 2025 results, along with upcoming Board changes that include planned departures and a defined end date for the current Chair. See our latest analysis for Adecco Group. The earnings and Board updates come after a weaker share price patch, with a 1-day share price return of 2.03% at CHF21.06, compared with a year-to-date share price return of 10.23% and a 1-year total shareholder return of...

Roche Holding (SWX:ROG) reported positive Phase II ZUPREME-1 results for petrelintide in chronic weight management, highlighting efficacy and safety data. Genentech, part of Roche Group, announced significant findings from the pivotal Phase III FENhance 1 study, with fenebrutinib showing meaningful effects in relapsing multiple sclerosis. Roche Holding, trading at around CHF351.5, is drawing attention as these two clinical updates arrive alongside a 20.0% return over the past year and a...

UBS Group has proposed changes to its Board of Directors, nominating Agustín Carstens and Luca Maestri. Several long serving directors are set to step down as the bank refreshes its governance structure. The board changes come while UBS continues integrating Credit Suisse and responding to evolving regulatory expectations. For investors watching SWX:UBSG, these board moves come with the shares at CHF30.59 and after a mixed run, with a 7.0% return over the past year alongside a 19.9% decline...

How VAT Group’s FY 2025 Numbers Set Up the Next Chapter VAT Group (SWX:VACN) has wrapped up FY 2025 with second half revenue of CHF 515.6 million and basic EPS of CHF 3.63, alongside trailing twelve month revenue of CHF 1.07 billion and EPS of CHF 7.15 framing the latest print. Over recent periods, the company has seen half yearly revenue move from CHF 492.6 million in 2H 2024 to CHF 515.6 million in 2H 2025, while half yearly EPS shifted from CHF 3.92 to CHF 3.63, and trailing twelve month...

What the latest earnings tell you about Zug Estates Holding Zug Estates Holding (SWX:ZUGN) just released full year 2025 figures, with sales of CHF 87.72 million, revenue of CHF 91.5 million, and net income of CHF 85.18 million drawing fresh investor attention. These headline numbers give you a fresh reference point for thinking about the stock, its current valuation, and how the business is converting its real estate and hotel activities into bottom line results. See our latest analysis for...

HIAG Immobilien Holding FY 2025 earnings snapshot HIAG Immobilien Holding (SWX:HIAG) has just posted its FY 2025 numbers, with first half revenue of CHF 47.6 million and basic EPS of CHF 4.42, while funds from operations came in at CHF 1.90 per share, giving investors a fresh read on both cash generation and headline profitability. Over recent periods the company has seen revenue move from CHF 70.3 million in the first half of 2024 to CHF 65.8 million in the second half of 2024 and then to...

What Holcim’s 2025 earnings mean for shareholders Holcim (SWX:HOLN) has moved into focus after reporting full year 2025 results, with sales of CHF 15,724 million compared to CHF 16,201 million a year earlier, and a sharp jump in reported net income and earnings per share. See our latest analysis for Holcim. Despite the strong headline earnings, Holcim’s 1 month share price return of an 18.15% decline and a 14% share price pullback year to date suggest momentum has cooled, even as the 1 year...

Implenia (SWX:IMPN) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 1.9b and basic EPS of CHF 1.80 setting the tone for how the year is shaping up. The company has seen revenue move from CHF 1.7b in the first half of 2024 to CHF 1.9b in the latest half, while basic EPS shifted from CHF 1.43 to CHF 1.80 over the same periods, creating a results season in which investors are weighing growth prospects against how efficiently those sales are turning into profit. See...

What Swisscom’s Recent Share Performance Tells You Swisscom (SWX:SCMN) has seen its share price move in recent weeks, with a 0.8% decline over the past day contrasting with gains over the past week, month and past 3 months. For context, the stock shows a 0.9% return over the past week, 12.3% over the past month and 28.2% over the past 3 months, with a 45.7% total return over the past year. See our latest analysis for Swisscom. The recent pullback in Swisscom’s share price to CHF714.5 comes...

Why Siegfried Holding’s latest earnings and leadership moves matter now Siegfried Holding (SWX:SFZN) has just released its full year 2025 results alongside a senior management reshuffle, a combination that gives you fresh information on both the business performance and how the company is being run. See our latest analysis for Siegfried Holding. The latest CHF82.5 share price comes after a 14.4% 90 day share price return and 10.4% year to date gain, even though the 1 year total shareholder...

SoftwareOne Holding (SWX:SWON) has been appointed one of the first global authorized Google Cloud distributors, with new distribution rights across 10 launch markets and extended support for partners using Google Cloud services. See our latest analysis for SoftwareOne Holding. The new Google Cloud distribution role arrives after a tough stretch for the share price, with a 30 day share price return of a 13.28% decline and a 90 day share price return of a 23.32% decline, even as the 1 year...

Idorsia (SWX:IDIA) reports materially higher sales for its insomnia drug Quvivic, reflecting stronger commercial traction. The company secures public reimbursement for Quvivic across additional key healthcare markets. Idorsia expands Quvivic access into new geographies while pursuing fresh partnerships and distribution agreements. Progress continues in its pediatric insomnia study and across several pipeline candidates in different therapeutic areas. Idorsia, a biopharmaceutical company...

Why Sensirion’s upcoming earnings are on investors’ radar Sensirion Holding (SWX:SENS) is drawing attention ahead of its 10 March 2026 earnings release, as investors watch how demand for sensors in AI and IoT devices shows up in the latest numbers. The focus is on how the company’s cash position and R&D spending support its role as a potential growth play in AI related hardware, and whether new guidance shifts sentiment around the stock. See our latest analysis for Sensirion Holding. Despite...

Alcon (SWX:ALC) is in the spotlight after reporting fourth quarter 2025 earnings, with higher sales and revenue alongside lower net income, while also proposing a dividend and drawing attention for its intraocular lens business. See our latest analysis for Alcon. Alcon’s share price is now at CHF65.24, with a 1 month share price return of 5.29% and a year to date share price return of 2.68%. The 1 year total shareholder return of 21.63% decline contrasts with modest 3 year and 5 year total...

In February 2026, Swiss Re reported full-year 2025 net income of US$4,740 million, sharply higher than the prior year, and announced a share repurchase program of up to US$1.50 billion authorized by its Board, running through December 31, 2026 subject to legal and regulatory approvals. Together with the appointment of Anne Lohbeck as chief risk officer for PC Re, these moves highlight Swiss Re's focus on capital return and risk oversight alongside improved profitability. We’ll now examine...

The EMA’s Committee for Medicinal Products for Human Use has issued a positive opinion for Novartis’s remibrutinib for chronic spontaneous urticaria. The recommendation supports marketing authorization in the EU for a highly selective oral BTK inhibitor targeting patients with unmet treatment needs. Novartis (SWX:NOVN) is a large global pharmaceutical group with a focus on immunology and other specialty therapies, so progress on remibrutinib fits squarely within its core franchise. For...

Kuehne + Nagel International (SWX:KNIN) FY 2025 Results: Margins In Focus After Softer Q4 Kuehne + Nagel International (SWX:KNIN) has wrapped up FY 2025 with fourth quarter revenue of CHF5.95b and basic EPS of CHF1.32, alongside net income of CHF157m. These results frame how investors may assess the full year at a share price of CHF180.45. The company’s quarterly revenue moved from CHF6.76b in Q4 2024 to CHF6.33b in Q1 2025 and then to CHF5.95b in Q4 2025, while basic EPS shifted from CHF2.50...

Roche Holding (SWX:ROG) is back in focus after Genentech reported that fenebrutinib met the primary endpoint in the pivotal Phase III FENhance 1 trial in relapsing multiple sclerosis, with statistically significant efficacy versus teriflunomide. See our latest analysis for Roche Holding. The fenebrutinib update lands after a series of drug pipeline milestones and conference appearances. It comes with a 90 day share price return of 15.7% and a 1 year total shareholder return of 22.3%, which...

Latest FY 2025 Results Snapshot SIG Group (SWX:SIGN) has posted a mixed FY 2025 picture, with second half revenue of €1.7b and a basic EPS loss of €0.47, while trailing twelve month revenue sits at €3.2b alongside a basic EPS loss of €0.23. The company has seen revenue move from €1.8b and basic EPS of €0.29 in the second half of 2024 to €1.7b and a basic EPS loss of €0.47 in the second half of 2025, highlighting pressure on earnings even as the business scale remains large. For investors, the...

Bucher Industries (SWX:BUCN) has posted fresh FY 2025 numbers, reporting first half revenue of CHF 1,537.3 million and basic EPS of CHF 13.98. This follows revenue of CHF 1,724 million and EPS of CHF 14.07 in the first half of 2024, and CHF 1,431.5 million with EPS of CHF 8.09 in the second half of 2024. The company has also reported trailing twelve month revenue between CHF 2,914.3 million and CHF 3,155.5 million, with TTM EPS ranging from CHF 22.06 to CHF 23.22, setting the scene for...

Temenos (SWX:TEMN) has drawn fresh attention after releasing its 2025 full year results together with an annual dividend announcement of CHF 1.40 per share, a combination many investors watch closely. See our latest analysis for Temenos. Temenos shares are trading at CHF 72.60, and the latest full year earnings together with the CHF 1.40 dividend announcement appear to have supported a 4.91% 1 month share price return, even though the year to date share price return is a decline of 10.92% and...

Why VAT Group’s latest earnings matter for shareholders VAT Group (SWX:VACN) reported record 2025 sales, EBITDA, and free cash flow, yet paired those figures with a cautious Q1 2026 revenue outlook that fell short of analyst expectations. That mix of strong historical results and softer near term guidance, along with an upbeat longer term view from management, has put the stock under closer scrutiny as investors reassess how much optimism is already reflected in the current share price. See...